MRD testing personalizes diffuse large B‑cell lymphoma therapy—shorten chemo for early responders and flag high‑risk patients for targeted add‑ons.
Hua-Jay "Jeff" Cherng, MD
Hua-Jay “Jeff” Cherng, MD is an assistant professor of medicine in the lymphoma program in the Division of Hematology and Oncology at the Columbia University Irving Medical Center.
Articles by Hua-Jay "Jeff" Cherng, MD
MRD testing promises sharper DLBCL response tracking than PET scans, cutting false positives, biopsies, and guiding therapy as trials catch up.
MRD testing in lymphoma grows fast, but varying assays and limited guidelines leave clinicians guessing; trials and standards clarify care.
Real-time ctDNA MRD testing guides early chemo de-escalation in diffuse large B-cell lymphoma, aiming to cut toxicity without losing cure rates.